Last Updated: June 22, 2026

RALOXIFENE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Raloxifene, and when can generic versions of Raloxifene launch?

Raloxifene is a drug marketed by Amneal Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms, Teva Pharms Usa, and Watson Labs Inc. and is included in eight NDAs.

The generic ingredient in RALOXIFENE is raloxifene hydrochloride. There are seventeen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Raloxifene

A generic version of RALOXIFENE was approved as raloxifene hydrochloride by TEVA PHARMS USA on March 4th, 2014.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for RALOXIFENE?
  • What are the global sales for RALOXIFENE?
  • What is Average Wholesale Price for RALOXIFENE?
Summary for RALOXIFENE
US Patents:0
Applicants:8
NDAs:8
Drug Prices: Drug price information for RALOXIFENE
DailyMed Link:RALOXIFENE at DailyMed
Drug patent expirations by year for RALOXIFENE
Drug Prices for RALOXIFENE

See drug prices for RALOXIFENE

Drug Sales Revenue Trends for RALOXIFENE

See drug sales revenues for RALOXIFENE

US Patents and Regulatory Information for RALOXIFENE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 208206-001 Apr 8, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms Usa RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 078193-001 Mar 4, 2014 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Glenmark Pharms Ltd RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204491-001 Mar 22, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Watson Labs Inc RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 200825-001 Jan 21, 2015 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 204310-001 Aug 28, 2015 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Cadila Pharms Ltd RALOXIFENE HYDROCHLORIDE raloxifene hydrochloride TABLET;ORAL 211324-001 Aug 18, 2020 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for RALOXIFENE
Raloxifene hcl manufacturers?
Raloxifene hydrochloride market?
Raloxifene drug classification?
Relaxofine raloxifene manufacturer?
Relaxofine raloxifene manufacturer?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links